Actively Recruiting
Evaluating Umbilical Cord Mesenchymal Stem Cell Therapy During Kasai Portoenterostomy for Infants with Biliary Atresia in a Randomized Controlled Trial
Led by Dr Cipto Mangunkusumo General Hospital · Updated on 2026-09-09
40
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Biliary atresia is a serious liver disease in infants that often requires liver transplantation once cirrhosis develops. This trial evaluates whether injecting umbilical cord-derived mesenchymal stem cells directly into the liver during the Kasai portoenterostomy surgery can be a safe and effective additional treatment. The study is a double-blind, randomized clinical trial focused on infants diagnosed with biliary atresia confirmed by intraoperative cholangiography. Participants are infants aged 30 to 90 days undergoing Kasai portoenterostomy and are randomly assigned to receive either injections of umbilical cord mesenchymal stem cells or a placebo solution directly into specific liver segments during surgery. The stem cells are delivered at a dose of 105 cells per kilogram of body weight. Both groups receive the standard Kasai surgical procedure to restore bile flow. After surgery, participants are monitored for 180 days to assess safety and liver function, including measurements of bilirubin levels, liver enzymes, blood counts, liver fibrosis stages, and incidence of postoperative complications like cholangitis. The study tracks jaundice clearance, liver stiffness, and survival outcomes to evaluate the effects of the stem cell treatment compared to placebo, with multiple assessments at baseline and several postoperative timepoints.
CONDITIONS
Brief Title
Umbilical Cord Mesenchymal Stem Cell Therapy for Biliary Atresia
Research Team
T
Tri Hening Rahayatri, MD, PhD
I
Irene Effendy, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here